MEDS Stock Surges As AI Health Ecosystem Gains Traction

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update ■ Third quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the s

DataMeds AI signed a non-binding LOI with six companies to acquire assets, licenses, and a controlling stake in HLH. The deal, pending approvals, would give the recipients 89.5% ownership, with shares as consideration. Closing is contingent on definitive agreements and a liability cap of $2 million. The LOI also includes royalty and governance terms, with REBOOT's transactions potentially closing separately.

DataMEDS AI (NASDAQ:MEDS) announced a non-binding LOI with Datavault AI (NASDAQ:DVLT), others, to acquire QOLPOM IP and expand its healthcare ecosystem. The deal aims to integrate health tracking, prescription delivery, and AI/blockchain tech, with a Q4 2026 target close. FDA guidance supports the optimization of DataMEDS' Health Lives Here app. The transaction is subject to due diligence and regulatory approvals.

DataMeds AI Inc. (NASDAQ: MEDS) stock surged 16.32% after securing Humana Medicaid coverage for its ChemoFx assay and reporting $1M in September revenue. The company also launched a GLP-1 focused app, driving investor interest. Despite weak fundamentals, including negative cash flow and equity, MEDS trades on news catalysts, with significant volatility.

DataMeds AI (NASDAQ:MEDS) welcomed the FDA's proposed policy to loosen restrictions on certain peptides, citing 6,500+ pharmacies. The company's subsidiary, Corexa Health, plans to capitalize on the regulatory shift, aiming to fill prescriptions and distribute peptides. DataMEDS sees significant growth potential in the peptide market, focusing on telemedicine and pharmacy services via its Health Lives Here app.

DataMeds AI (MEDS) settled litigation, repurchased 364,099 shares for $350,000, and issued 666,667 shares in a tech license deal. The company's stockholders' equity now exceeds $2.5M, with $19M in liabilities extinguished.